S&P 500
7,507.80
-0.22%
Dow Jones
51,595.40
-0.32%
Nasdaq 100
30,411.80
-0.23%
Russell 2000
2,975.48
-0.09%
FTSE 100
10,384.80
-0.34%
Nikkei 225
71,987.20
+0.02%

Investing

Profits to Fall Sharply at Lilly (LLY)

Photo of Paul Ausick
By Paul Ausick Published

Profits at Eli Lilly & Co. (NYSE: LLY) in 2012 will be sharply lower than analysts had been expecting. The drug maker, which lost patent protection on its best-selling anti-psychotic drug Zyprexa in late 2011, forecasts that it will post 2012 full-year EPS of $3.10-$3.20, where the consensus estimate from analysts was EPS of $3.61.

The company confirmed that it expects to meet or exceed 2011 EPS guidance of $4.30-$4.35, excluding items.

Zyprexa generated about $5 billion in 2010 sales for Lilly, and the company’s other best seller, Cymbalta, generated $3.5 billion in the same year. Cymbalta loses patent protection at the end of 2013. Lilly is in final stage trials with an Alzheimer drug and new drugs for diabetes and cancer.

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Paul Ausick |

Lilly’s Drugs Closer to Edge of Patent Cliff (LLY, PFE, JNJ, BMY, SNY, MRK)

Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better…

Paul Ausick |

Lilly Earnings Dive on Patent Expiration (LLY)

Drug maker Eli Lilly & Co. reported fourth quarter and full year earnings this morning, and although revenues were higher…

Paul Ausick |

FDA OKs Generic Version of Lilly Drug (LLY)

Indian drug maker Sun Pharmaceutical Industries Ltd. has received approval from the US Food and Drug Administration to sell its…

Paul Ausick |

Top 10 U.S. Drugs for 2012 First Quarter

Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for…

Big Dividend Pharmaceutical Stock Now Jefferies Top Global Sector Pick
Lee Jackson |

Big Dividend Pharmaceutical Stock Now Jefferies Top Global Sector Pick

In a new research report, Jefferies shuffles some of the pharmaceutical stocks in its coverage universe and a beaten-down dividend…

Trey Thoelcke |

Generics Take a Bite of Eli Lilly Q3 Results

Eli Lilly (NYSE: LLY) this morning reported disappointing third-quarter results as generic drugs took a toll on its sales. The…

Pharmaceutical Stocks May Be the Best Total Return Play: 3 to Buy Now
Lee Jackson |

Pharmaceutical Stocks May Be the Best Total Return Play: 3 to Buy Now

With yields plunging and the market getting very pricey, some top pharmaceutical stocks are starting to look like a great…

Douglas A. McIntyre |

Lipitor OTC: What Next? (PFE, MRK, AZN, SNY, BMY, LLY, JNJ, AMGN)

Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability.…

Merrill Lynch US 1 List On Sale: 4 Top Dividend Stocks to Buy Now
Lee Jackson |

Merrill Lynch US 1 List On Sale: 4 Top Dividend Stocks to Buy Now

24/7 Wall St. screened the list of the top Merrill Lynch picks for the dividend yielding stocks that are on…

Top Gaining Stocks

CarMax
KMX • Vol: 7,330,419
Corning
GLW • Vol: 22,800,969
Intel
INTC • Vol: 233,719,006
Super Micro Computer
SMCI • Vol: 68,465,534
Enphase Energy
ENPH • Vol: 13,978,376

Top Losing Stocks

Accenture
ACN • Vol: 41,744,333
EPAM Systems
EPAM • Vol: 5,636,587
Cognizant
CTSH • Vol: 61,311,400
Coterra Energy
CTRA • Vol: 73,319,495
Kroger
KR • Vol: 26,704,230